Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Posts
- Category: Articles (continued)
- Study Uncovers How Parkinson's Disease Spreads
- Study: New Huntington’s Treatment Shows Promise
- Surprising Discovery: Brain Variants of Protein Associated with Huntington's and Other Neurodegenerative Diseases Identified
- Suven Life Sciences Secures 4 Product Patents For Their NCEs In China And Korea
- Suven Life secures (2) Product Patents for their NCEs in New Zealand
- Suven Life Secures 4 Product Patents For Their NCEs
- Svolta per l’Alzheimer, trovata sostanza che blocca i danni al cervello
- Synthetic Oil Drug May Bring Promise for Huntington’s Disease
- Systematic Interaction Network Filtering in Biobanks: MDC Neurobiologists Identify Protective Protein against Huntington’s Disease
- Teaching An Old Protein New Tricks: Developing A Novel Gene Therapy For Huntington's Disease
- TEAM HOPE 2012!
- TELETHON ASSEGNATI I FONDI PER LA RICERCA SCIENTIFICA
- Tetrabenazine in the therapy of choreic movements: the point of view of Jo Jankovic
- Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia
- Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology
- Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia
- Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease
- Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease
- Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
- Teva Expands Central Nervous System (CNS) Development Pipeline with Acquisition of Huntexil® Development Program Rights from NeuroSearch A/S
- Teva Pharm gets approval in China for Huntington's treatment
- Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.
- Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease
- Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
- Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous Measurement & Analysis of Huntington Disease Symptoms in Collaboration with Intel
- Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson’s Disease and Movement Disorders
- The best news for the Huntington's disease community since the discovery of the gene: Ionis trial data revealed, Roche confirms jump to Phase 3
- The Faces of Huntington's Disease - July 2012
- The Faces of Huntington's Disease The Huntington's Disease Project Magazine!
- The first dose is hope: moving towards treatments for Huntington’s disease
- The Huntington Study Group announces first-HD study
- The Huntington's Disease Project - 2012 Trailer (Italian Version)
- The Huntington’s Disease Project
- The Huntington’s Disease Project
- The incredible lightness – and responsibility – of exiting the Huntington’s closet
- The Lancet Neurology publishes Prana’s Huntington’s Disease Trial
- The Lancet Neurology: Scientists Identify Early Predictors of Huntington’s Disease Progression Wake Forest Neurologist Applauds Research
- The messenger in Huntingon's disease
- The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019
- The Potential for New Therapeutic Approaches: Global Research Collaboration Examines Multiple Pathways of Neuroprotection in Huntington Disease
- The precious participation of the Huntington’s disease community in the quest for treatments: a report on the 2015 HD Therapeutics Conference
- The right mouse model is crucial for Huntington's disease drug development
- The UCL Huntington’s Disease Centre
- Thomson Reuters Partners with CHDI Foundation to Develop Systems Biology Tools for Huntington's Disease
- Thousands Join Lundbeck and the Hereditary Disease Foundation to Build Hope for Huntington’s Disease
- Toward a Salivary Biomarker for Huntington Disease
- Treating Huntington’s disease: making new neurons is not enough
- Treating MS Without Dangerous Drugs
- Treatments For Neurodegenerative Disorders - Global Forecast, Market Share, Size, Growth And Industry Analysis, 2012 - 2018
- Tribute to Marina Frontali, 1941-2021
Plugin by dagondesign.com
